News Channels

07 Aug 2017 Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
07 Aug 2017 Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
07 Aug 2017 Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures
07 Aug 2017 Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients
07 Aug 2017 Alligator expands immuno-oncology collaboration with Stanford University
07 Aug 2017 Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer
07 Aug 2017 FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
07 Aug 2017 MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
05 Aug 2017 Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice
05 Aug 2017 MiMedx Files With The FDA To Initiate Its Investigational New Drug Achilles Tendonitis Phase 3 Clinical Trial
05 Aug 2017 Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine
04 Aug 2017 Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
04 Aug 2017 SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
04 Aug 2017 Portola Pharmaceuticals Announces Resubmission of Biologics License Application for AndexXa® (Andexanet Alfa)
04 Aug 2017 FDA Advisory Committee Votes in Favor of XELJANZ® (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis
04 Aug 2017 AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
04 Aug 2017 Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
03 Aug 2017 VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers
03 Aug 2017 Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies
03 Aug 2017 Foamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing